New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings...

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns -- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases ---- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at...

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening...

Early Treatment Program for Opioid-Dependent Newborns Significantly Reduces Cost While Maintaining Medical and Safety Outcomes OAKBROOK TERRACE, Ill., May 03, 2018 (GLOBE NEWSWIRE) -- Prescription and non-prescription opioid use and dependence are increasing in women of childbearing age and during pregnancy.1 Fetal opioid...

Global Healing to Donate Life-Saving Phototherapy Light Meters to Developing Countries BERKELEY, CA--(Marketwire - October 4, 2010) -  Global Healing, a leading non-profit organization devoted to providing modern medical equipment, training and supplies to the developing world,...